What is Puma Biotechnology Inc Annual Revenue?

Puma Biotechnology Inc Annual Revenue fell 2.19%, in the last year to $230.47 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

What is Puma Biotechnology Inc Annual Net Profit?

Puma Biotechnology Inc Annual Net Profit rose 40.23% in the last year to $30.28 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is Puma Biotechnology Inc Price to Earning Ratio?

Puma Biotechnology Inc Price to Earning Ratio is 4.74, higher than its sector PE ratio of 3.14.

What is Puma Biotechnology Inc Stock Price?

Puma Biotechnology Inc Stock Price fell 42.32% and underperformed its sector by 50.82% in the past year.

What is Puma Biotechnology Inc Quarterly Revenue?

Puma Biotechnology Inc Quarterly Revenue fell 18.15% YoY to $59.08 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

What is Puma Biotechnology Inc Quarterly Net profit?

Puma Biotechnology Inc Quarterly Net profit rose 57.36% YoY to $19.3 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

What is Puma Biotechnology Inc Debt to Equity Ratio?

Puma Biotechnology Inc Debt to Equity Ratio of 0.8 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Puma Biotechnology Inc Return on Equity(ROE)?

Puma Biotechnology Inc Return on Equity(ROE) for the last financial year was 41.6%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

What is Puma Biotechnology Inc Mutual Fund Holding?

Puma Biotechnology Inc Mutual Fund Holding increased by 1.24% in the last quarter to 32.09.

What is Puma Biotechnology Inc Promoter Share Holding?

Puma Biotechnology Inc Promoter Share Holding increased by 0.75% in the most recent quarter to 21%.

What is Puma Biotechnology Inc Interest Coverage Ratio?

Puma Biotechnology Inc Interest Coverage Ratio is 2.94, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

How is the Puma Biotechnology Inc today?

The Puma Biotechnology Inc today is trading in the green, up by 1.05% at 2.89.

How has Puma Biotechnology Inc performed historically?

The Puma Biotechnology Inc is currently trading up 1.05% on an intraday basis in the past week the index fell -1.37%. The index has been down -3.02% in the past quarter and fell -42.32% in the past year. You can view this in the overview section.

Puma Biotechnology Inc XNAS: PBYI

Puma Biotechnology Inc Live Share Price Today, Share Analysis and Chart

Name: Puma Biotechnology Inc: Is Infosys Ltd. worth buying?
Item: Puma Biotechnology Inc
Rating: 3.2573055
Author: Trendlyne DVM scores

Strong Performer, Under Radar

Download real time

2.89 0.03 (1.05%)

45.88% Fall from 52W High

30,148 XNAS Volume

XNAS 22 Apr, 2025 10:49 AM (EDT)

Board Meeting

The next board meeting for Puma Biotechnology Inc is on 02 May 2025 for the purpose of Puma Biotechnology Inc First Quarter Earnings Results for 2025 See details

Puma Biotechnology Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	143.4
PE TTM High in industry Unavailable in chosen country	4.7
PEG TTM Below industry Median Unavailable in chosen country	0.1
Price to Book Below industry Median Unavailable in chosen country	1.6
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	50.1
Revenue Growth Qtr YoY % Negative Revenue Growth Qtr YoY % Unavailable in chosen country	-18.2
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-2.2
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	57.4
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	40.2
Operating Profit Margin Qtr % Below industry Median Unavailable in chosen country	22.6
Operating Profit Margin TTM % Below industry Median Unavailable in chosen country	13.4
Piotroski Score High in industry Unavailable in chosen country	6
Rel Perf vs Sector quarter% Unavailable in chosen country	-1.9
ROE Annual % High in industry Unavailable in chosen country	41.6
RoA Annual % High in industry Unavailable in chosen country	13.6

All financials are in USD Million and price data in USD

High Financial Strength

72.2 / 100

Affordable Valuation

72.0 / 100

Technically Neutral

44.1 / 100

Strong Performer, Under Radar These stocks are with good quality scores and with strong financials. They are affordably priced stocks and can give good returns View Similar Embed DVM

1Yr Price target upside is 50%

3 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Strong Buy Zone

0.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Puma Biotechnology Inc Stock Price Analysis

Day Price Range 1.0% 1 Day return Unavailable in chosen country	2.9 (LTP) 2.92.9 LowHigh
Week Price Range -1.4% 1 Week return Unavailable in chosen country	2.9 (LTP) 2.83 LowHigh
Month Price Range -17.7% 1 Month return Unavailable in chosen country	2.9 (LTP) 2.63.6 LowHigh
52 Week Price Range -42.3% 1 Year return Unavailable in chosen country	2.9 (LTP) 2.25.3 LowHigh

View full Share Price History

Puma Biotechnology Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Puma Biotechnology Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

0.6

Avg. Estimate

0.4

Low Estimate

0.3

High Estimate

0.5

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 35.5% in FY25

Consensus Recommendation

3 ANALYST Recommendations

HOLD

The consensus recommendation from 3 analysts for Puma Biotechnology Inc is HOLD

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Puma Biotechnology Inc Stock Analysis

Puma Biotechnology Inc stock analysis with key metrics, changes, and trends.

Puma Biotechnology Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$230.47 M	2.19%	negative	Annual Revenue fell 2.19%, in the last year to $230.47 M. Its sector's average revenue growth for the last fiscal year was 7.49%.
Annual Net Profit	$30.28 M	40.23%	positive	Annual Net Profit rose 40.23% in the last year to $30.28 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	4.74	-	negative	Price to Earning Ratio is 4.74, higher than its sector PE ratio of 3.14.
Stock Price	$2.89	-42.32%	negative	Stock Price fell 42.32% and underperformed its sector by 50.82% in the past year.
Quarterly Revenue	$59.08 M	18.15%	negative	Quarterly Revenue fell 18.15% YoY to $59.08 M. Its sector's average revenue growth YoY for the quarter was 5.79%.
Quarterly Net profit	$19.3 M	57.36%	positive	Quarterly Net profit rose 57.36% YoY to $19.3 M. Its sector's average net profit growth YoY for the quarter was -41.98%.
Debt to Equity Ratio	0.8	-	positive	Debt to Equity Ratio of 0.8 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	41.60 %	41.6%	positive	Return on Equity(ROE) for the last financial year was 41.6%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.
Mutual Fund Holding	32.09 %	1.24%	positive	Mutual Fund Holding increased by 1.24% in the last quarter to 32.09.
Promoter Share Holding	21.00 %	0.75%	positive	Promoter Share Holding increased by 0.75% in the most recent quarter to 21%.
Interest Coverage Ratio	2.94	-	positive	Interest Coverage Ratio is 2.94, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

VIEW LESS

Loading data..

Puma Biotechnology Inc - Company Profile

What does Puma Biotechnology Inc do?

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Puma Biotechnology Inc Management structure

All Gross Remunerations are in USD

Mr. Alan H. Auerbach

Chairman of the Board, President, Chief Executive Officer and Secretary

2024

Gross Remuneration

Year

Mr. Maximo F. Nougues

Chief Financial Officer and Principal Accounting Officer

2024

Gross Remuneration

2024

Gross Remuneration

Year

Puma Biotechnology Inc Live Share Price Today, Share Analysis and Chart

45.88% Fall from 52W High

Puma Biotechnology Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Puma Biotechnology Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Puma Biotechnology Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Puma Biotechnology Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to reduce by 35.5% in FY25

Consensus Recommendation

The consensus recommendation from 3 analysts for Puma Biotechnology Inc is HOLD

Puma Biotechnology Inc Stock Analysis

Puma Biotechnology Inc stock analysis with key metrics, changes, and trends.

Annual Revenue fell 2.19%, in the last year to $230.47 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit rose 40.23% in the last year to $30.28 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is 4.74, higher than its sector PE ratio of 3.14.

Stock Price fell 42.32% and underperformed its sector by 50.82% in the past year.

Quarterly Revenue fell 18.15% YoY to $59.08 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit rose 57.36% YoY to $19.3 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Debt to Equity Ratio of 0.8 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was 41.6%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 1.24% in the last quarter to 32.09.

Promoter Share Holding increased by 0.75% in the most recent quarter to 21%.

Interest Coverage Ratio is 2.94, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Puma Biotechnology Inc - Company Profile

What does Puma Biotechnology Inc do?

Puma Biotechnology Inc Management structure

Mr. Alan H. Auerbach

Chairman of the Board, President, Chief Executive Officer and Secretary

Mr. Maximo F. Nougues

Chief Financial Officer and Principal Accounting Officer

Puma Biotechnology Inc Board of directors

Mr. Alan H. Auerbach

Chairman of the Board, President, Chief Executive

Mr. Michael Patrick Miller

Independent Director

Mr. Jay M. Moyes

Lead Independent Director

Dr. Troy E. Wilson, PhD, J.D.

Independent Director

Dr. Adrian M. Senderowicz, M.D.

Independent Director